

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

ROXANE LABORATORIES, INC.  
Petitioner

v.

NOVARTIS AG  
Patent Owner

---

Case No. To Be Assigned  
Patent No. 9,006,224

---

**PETITION FOR INTER PARTES REVIEW OF  
U.S. PATENT NO. 9,006,224**

## TABLE OF CONTENTS

I.	INTRODUCTION .....	1
II.	MANDATORY NOTICES PURSUANT TO 37 C.F.R. § 42.8 .....	4
	A. Real Party-In-Interest .....	4
	B. Related Matters.....	4
	C. Lead And Backup Counsel.....	5
	D. Service Information.....	6
III.	PAYMENT OF FEES .....	6
IV.	REQUIREMENTS UNDER 37 C.F.R. § 42.104.....	6
	A. Grounds For Standing .....	6
	B. Identification Of Challenge And Precise Relief Requested.....	7
	1. Claims For Which <i>Inter Partes</i> Review Is Requested.....	7
	2. The Prosecution History Of The '224 Patent .....	8
	a. Non-Final Office Action (February 16, 2011) .....	8
	b. Response (August 2, 2011).....	9
	c. Final Office Action (October 13, 2011) .....	9
	d. Response After Final Office Action (January 13, 2012) .....	10
	e. Request For Continued Examination And Declaration Filed February 6, 2012 In Support Of Non-Obviousness.....	11
	f. Non-Final Office Action (May 9, 2014).....	11
	g. Response (November 7, 2014) .....	12
	3. Statutory Grounds On Which The Challenge Is Based .....	13
	4. Evidence Relied Upon To Support The Challenge.....	14
	5. How The Challenged Claims Are To Be Construed .....	14
V.	DESCRIPTION OF THE PURPORTED INVENTION.....	14
VI.	CLAIM CONSTRUCTION .....	15
	A. Applicable Law .....	15
	B. Construction Of Claim Terms.....	17
VII.	PERSON HAVING ORDINARY SKILL IN THE ART .....	17

VIII.	TECHNICAL BACKGROUND AND STATE OF THE ART .....	18
A.	The Biology Of PNETs .....	19
B.	Everolimus As A Treatment For PNET .....	22
C.	The Prior Art Taught That Everolimus Has Enhanced Solubility And Pharmacokinetics Compared To Rapamycin .....	26
IX.	THE SCOPE AND CONTENT OF THE PRIOR ART .....	27
A.	U.S. Patent No. 5,665,772 .....	27
B.	U.S. Publication No. 2004/0147541 .....	29
C.	Tabernero .....	30
D.	Dutcher .....	31
E.	von Wichert .....	32
X.	THE PERTINENT LAW REGARDING MOTIVATION TO COMBINE THE PRIOR ART REFERENCES .....	33
XI.	PRECISE REASONS FOR THE RELIEF REQUESTED .....	34
A.	Ground 1: Claims 1 And 2 Are Invalid Under 35 U.S.C. § 103 On The Ground That They Are Rendered Obvious Over The ’541 Publication In View Of Tabernero .....	35
1.	Claim 1 Of The ’224 Patent Is Obvious Over The ’541 Publication In View Of Tabernero .....	36
a.	The Prior Art Taught That Everolimus Decreases PNET Growth .....	36
b.	The Prior Art Taught That Everolimus Is Safe And Efficacious Against Solid Tumors In Humans .....	38
2.	Claim 2 Of The ’224 Patent Is Obvious Over The ’541 Publication In View Of Tabernero .....	39
B.	Ground 2: Claims 1 And 2 Are Invalid Under 35 U.S.C. § 103 On The Ground That They Are Rendered Obvious Over von Wichert In View Of Dutcher, The ’772 Patent And Tabernero .....	40
1.	Claim 1 Of The ’224 Patent Is Obvious Over von Wichert In View Of Dutcher, The ’772 Patent And Tabernero .....	40
a.	The Prior Art Taught That Rapamycin Is Efficacious Against PNET Cells .....	40
b.	The Prior Art Taught That Everolimus And Rapamycin Have Similar Antitumor Properties .....	41

c.	The Prior Art Taught That Everolimus Has Increased Solubility And Improved Pharmacokinetic Properties Compared To Rapamycin .....	42
d.	The Prior Art Taught That Everolimus Is Safe And Efficacious Against Solid Tumors In Humans .....	43
2.	Claim 2 Of The '224 Patent Is Obvious Over von Wichert In View Of Dutcher, The '772 Patent And Tabernero .....	44
XII.	SECONDARY CONSIDERATIONS DO NOT RENDER CLAIMS 1 AND 2 NONOBVIOUS .....	45
A.	The Methods Claimed In The '224 Patent Produced No Relevant Unexpected Results .....	46
B.	The '224 Patent Did Not Satisfy Any Long Felt But Unmet Need, And The Sales Of Afinitor <sup>®</sup> (Everolimus) Tablets Do Not Evidence Commercial Success.....	48
C.	Copying By Generic Drug Makers Is Irrelevant.....	49
XIII.	CONCLUSION.....	49

## EXHIBIT LIST

Exhibit No.	Description
1001	U.S. Patent No. 9,006,224 (“the ’224 Patent”)
1002	Excerpts from File History for the ’224 Patent
1003	Declaration of Dr. Kenneth H. Yu in Support of Petition for <i>Inter Partes</i> Review of U.S. Patent No. 9,006,224 (“Yu Declaration”)
1004	Curriculum Vitae of Dr. Kenneth H. Yu
1005	U.S. Patent Application Publication No. 2004/0147541 A1 (“the ’541 Publication”)
1006	Taberbero <i>et al.</i> , <i>A phase I study with tumor molecular pharmacodynamics (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors</i> , DEVELOPMENTAL THERAPEUTICS: MOLECULAR THERAPEUTICS, Abstract 3007, 193s (2005) (“Taberbero”)
1007	von Wichert <i>et al.</i> , <i>Insulin-like Growth Factor-I is an Autocrine Regulator of Chromogranin A Secretion and Growth in Human Neuroendocrine Tumor Cells</i> , CANCER RESEARCH, 60: 4573-4581 (August 15, 2000) (“von Wichert”)
1008	Dutcher, <i>Mammalian Target of Rapamycin (mTOR) Inhibitors</i> , CURRENT ONCOLOGY REPORTS, 6: 111-115 (2004) (“Dutcher”)
1009	U.S. Patent No. 5,665,772 (“the ’772 Patent”)
1010	Doran <i>et al.</i> , <i>Epidemiology of Pancreatic Neuroendocrine Tumours</i> , in PANCREATIC DISEASE: BASIC SCIENCE AND CLINICAL MANAGEMENT, 5 (Johnson <i>et al.</i> eds., 2004) (“Doran”)
1011	Guo <i>et al.</i> , <i>Frequent overexpression of cyclin D1 in sporadic pancreatic endocrine tumours</i> , JOURNAL OF ENDOCRINOLOGY, 179: 73-79 (2003) (“Guo”)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.